171 completed, 154 unknown, 137 recruiting, 59 not yet recruiting. 352 Phase 2, 109 Phase 1, 79 Phase 3, 49 Not applicable, 3 Early Phase 1.
Follow Esophageal Squamous Cell Carcinoma: new trials by email Literature Review of Esophageal Squamous Cell Carcinoma trials Research Report on Esophageal Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PhII Study of Toripalimab Followed by Definitive CRT & Adjuvant Toripalimab in Locally Advanced ESCC Toripalimab, Carboplatin + Paclitaxel - Esophageal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Vanderbilt-Ingram Cancer Center | 20 | 2026-12-31 | 2026-09-23 |
| Risk of Esophageal Cancer Returning After Immunotherapy, Chemotherapy, and Surgery Esophageal Squamous Cell Carcinoma (ESCC) | Not yet recruiting | Peking University Cancer Hospital & Institute | 100 | 2026-10-01 | 2026-09-16 | |
| Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell Carcinoma Sacituzumab tirumotecan, Toripalimab - Esophageal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Hebei Medical University Fourth Hospital | 33 | 2026-10-01 | 2026-09-16 |
| A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC Tislelizumab, Oxaliplatin, Leucovorin - Advanced Esophageal Squamous Cell Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | BeOne Medicines | 30 | 2026-09-14 | 2026-10-26 |
| A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors ASP388B, Pembrolizumab, Carboplatin - Locally Advanced or Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Astellas Pharma Global Development, Inc. | 392 | 2026-09-02 | 2026-10-26 |
| Immunotherapy Plus Anlotinib After Surgery for Esophageal Squamous Cell Cancer With Residual Tumor and Positive Lymph Nodes Anlotinib, Anti-PD-1 Monoclonal Antibody - Esophageal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Shanghai Chest Hospital | 75 | 2026-09-01 | 2026-09-21 |
| Standardized MRI and Structured Reporting for Esophageal Squamous Cell Carcinoma Standardized 3.0-T Esophageal Magnetic Resonance Imaging - Esophageal Squamous Cell Carcinoma | Not yet recruiting | The First Affiliated Hospital of Zhengzhou University | 500 | 2026-09-01 | 2026-08-18 | |
| Retlirafusp Alfa Combined With Chemoradiotherapy in Unresectable ESCC Induction chemo-immunotherapy, Concurrent chemoradiotherapy (cCRT), maintenance immunotherapy - Esophageal Squamous Cell Cancer | Not applicable | Not yet recruiting | RenJi Hospital | 68 | 2026-09-01 | 2026-08-18 |
| Paclitaxel Polymeric Micelles and Cisplatin Plus Sintilimab as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma Paclitaxel polymer micelles for injection and cisplatin combined with sintilimab - Esophageal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Hebei Medical University Fourth Hospital | 32 | 2026-09-01 | 2026-09-02 |
| Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma Sacituzumab Tirumotecan + Tagitanlimab - ESCC, Gastric Adenocarcinoma | Phase 2 | Not yet recruiting | Sun Yat-sen University | 75 | 2026-08-31 | 2026-07-14 |
| Radiotherapy Target Volume Delineation in Locally Advanced Esophageal Cancer in the Immunotherapy Era GTV-CTV Longitudinal Margin, Regional Lymph Node Irradiation Strategy - Esophageal Squamous Cell Carcinoma | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 500 | 2026-08-23 | 2026-10-05 | |
| Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Immunochemotherapy for Resectable Esophageal Cancer: A Target Trial Emulation Study Radiotherapy, Platinum-based Chemotherapy, PD-1 Inhibitor - Esophageal Squamous Cell Carcinoma (ESCC) | Not yet recruiting | Henan Cancer Hospital | 400 | 2026-08-20 | 2026-08-21 | |
| Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma Camrelizumab, Esophagectomy, Sample - Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 45 | 2026-08-17 | 2026-10-02 |
| SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma SKB500, Tislelizumab, Cisplatin - Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 120 | 2026-08-13 | 2026-10-20 |
| Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal Cancer Ipilimumab (1mg/kg), Sinitilimab, Nab-paclitaxel + Cisplatin - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 2 | Recruiting | Sun Yat-sen University | 51 | 2026-08-01 | 2026-08-07 |
| Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase II Becotatug Vedotin, Tislelizumab, Lenvatinib - Esophageal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 36 | 2026-08-01 | 2026-07-16 |
| Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC Adebrelimab, Nab paclitaxel, Carboplatin - Esophageal Cancer | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 120 | 2026-07-31 | 2026-07-29 |
| A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) HS-20093 for Injection, Irinotecan; Paclitaxel; Docetaxel - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 3 | Not yet recruiting | Hansoh BioMedical R&D Company | 494 | 2026-07-31 | 2026-06-02 |
| Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer Sacituzumab Tirumotecan (SKB264) plus Tislelizumab - Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | Shanghai Chest Hospital | 28 | 2026-07-30 | 2026-09-10 |
| Clinical Application of an AI-based Dissection Trajectory Prediction System (ADTPS) in Endoscopic Submucosal Dissection AI-based Dissection Trajectory Prediction System (ADTPS), Conventional ESD Procedure - Esophageal Squamous Cell Carcinoma (ESCC), High-Grade Intraepithelial Neoplasia | Not applicable | Active not recruiting | Qilu Hospital of Shandong University | 220 | 2026-07-29 | 2026-10-15 |
Showing 20 of 623. Sign in to see all of them.
Esophageal Neoplasms (152) · Adenocarcinoma Of Esophagus (95) · Squamous Cell Carcinoma of Head and Neck (45) · Carcinoma, Non-Small-Cell Lung (39) · Stomach Neoplasms (33) · Colorectal Neoplasms (28) · Uterine Cervical Neoplasms (22) · Neoplasm Metastasis (20) · Carcinoma, Hepatocellular (19) · Melanoma (17) · Triple Negative Breast Neoplasms (17) · Small Cell Lung Carcinoma (15) · Carcinoma, Squamous Cell (13) · Neoplasms (13)
Neoplasms, Glandular and Epithelial (623) · Digestive System Diseases (622) · Neoplasms by Histologic Type (622) · Neoplasms by Site (622) · Carcinoma (621) · Digestive System Neoplasms (621) · Gastrointestinal Diseases (621) · Neoplasms, Squamous Cell (620) · Gastrointestinal Neoplasms (618) · Esophageal Diseases (615) · Head and Neck Neoplasms (614) · Carcinoma, Squamous Cell (610) · Neoplasms (610) · Esophageal Neoplasms (471) · Respiratory Tract Diseases (47)
Cisplatin (125) · Radiotherapy (87) · Paclitaxel (80) · Fluorouracil (65) · Carboplatin (47) · Drug Therapy (40) · pembrolizumab (37) · Irinotecan (33) · tislelizumab (31) · Docetaxel (26) · toripalimab (26) · Neoadjuvant Therapy (25) · Oxaliplatin (25) · 130-nm albumin-bound paclitaxel (21) · Radiation (21)
Fudan University (34) · Sun Yat-sen University (29) · Peking University (17) · Tianjin Medical University Cancer Institute and Hospital (15) · The First Affiliated Hospital of Zhengzhou University (14) · Hebei Medical University Fourth Hospital (11) · Shanghai Chest Hospital (11) · Memorial Sloan Kettering Cancer Center (10) · Shanghai Zhongshan Hospital (10) · Sichuan Cancer Hospital and Research Institute (10) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (9) · Sichuan University (9) · Zhejiang Cancer Hospital (9) · Peking University Cancer Hospital & Institute (8) · Samsung Medical Center (8)
China (364) · United States (133) · South Korea (43) · France (41) · Taiwan (38) · Spain (30) · Japan (29) · United Kingdom (28) · Germany (22) · Italy (22) · Belgium (20) · Canada (15) · Australia (14) · Singapore (12) · Netherlands (11)
David H. Ilson, MD, PhD (8) · Hui Liu, Professor (5) · Lin Shen, MD (5) · Mian Xi, MD (4) · Shegan Gao, Doctor (4) · Tanyou Shan, Master (4) · Thomas Ruhstaller, MD (4) · Xiaozhi Yuan, Master (4) · Dan Wang, Master (3) · Feng Wang (3)
PMID 36990609, PMID 26254683, PMID 30089078, PMID 33373868, PMID 41309527, PMID 18309943, PMID 19465425, PMID 21684205, PMID 24982463, PMID 26808342, PMID 28742685, PMID 33538338, PMID 34160577, PMID 34454674, PMID 35440464, PMID 38710003, PMID 40373876, PMID 40467307, PMID 41531940, PMID 42580817, PMID 11208820, PMID 11391598, PMID 11870157, PMID 12049861, PMID 12167786, PMID 12771885, PMID 12885811, PMID 14759776, PMID 15151953, PMID 15533252, PMID 15800321, PMID 16129366, PMID 16235286, PMID 16515704, PMID 16601427, PMID 17921712, PMID 18270704, PMID 18574157, PMID 18640307, PMID 18845990, PMID 19738454, PMID 20016233, PMID 20068171, PMID 20304399, PMID 20502056, PMID 20975604, PMID 21205757, PMID 21464865, PMID 21507583, PMID 21673875
2023 (7), 2019 (5), P30CA043703 (3), 2016 (2), 2017 (2), 2018 (2), P30CA006927 (2), P30CA008748 (2), P30CA069533 (2), U10CA032102 (2), 2009 (1), 2015 (1), 2025 (1), 5UH3CA211457-04 (1), I01CX002349 (1)